JP2007525213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007525213A5 JP2007525213A5 JP2006550367A JP2006550367A JP2007525213A5 JP 2007525213 A5 JP2007525213 A5 JP 2007525213A5 JP 2006550367 A JP2006550367 A JP 2006550367A JP 2006550367 A JP2006550367 A JP 2006550367A JP 2007525213 A5 JP2007525213 A5 JP 2007525213A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- polypeptide
- seq
- nucleic acid
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 150000007523 nucleic acids Chemical group 0.000 claims 20
- 108091033319 polynucleotide Proteins 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 20
- 239000002157 polynucleotide Substances 0.000 claims 20
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 15
- 238000000034 method Methods 0.000 claims 11
- 208000020446 Cardiac disease Diseases 0.000 claims 5
- 208000019622 heart disease Diseases 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 3
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 claims 3
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 claims 3
- 206010019280 Heart failures Diseases 0.000 claims 3
- 238000001514 detection method Methods 0.000 claims 3
- 238000003018 immunoassay Methods 0.000 claims 3
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000003748 differential diagnosis Methods 0.000 claims 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 238000003127 radioimmunoassay Methods 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 108091093088 Amplicon Proteins 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 208000009525 Myocarditis Diseases 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000003683 cardiac damage Effects 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000003709 heart valve Anatomy 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000002055 immunohistochemical effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004080 milk Anatomy 0.000 claims 1
- 239000008267 milk Substances 0.000 claims 1
- 235000013336 milk Nutrition 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000001138 tear Anatomy 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53912704P | 2004-01-27 | 2004-01-27 | |
| US62201604P | 2004-10-27 | 2004-10-27 | |
| US62232004P | 2004-10-27 | 2004-10-27 | |
| US62819004P | 2004-11-17 | 2004-11-17 | |
| PCT/IB2005/000995 WO2005072055A2 (en) | 2004-01-27 | 2005-01-27 | Novel brain natriuretic peptide variants and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007525213A JP2007525213A (ja) | 2007-09-06 |
| JP2007525213A5 true JP2007525213A5 (https=) | 2008-03-21 |
Family
ID=38556367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006550367A Pending JP2007525213A (ja) | 2004-01-27 | 2005-01-27 | 新規の脳性ナトリウム利尿ペプチドの変異体及びその利用方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2007525213A (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120208756A1 (en) | 2009-07-23 | 2012-08-16 | Igisu Co., Ltd | Composition for external preparation for skin |
| WO2011024973A1 (ja) | 2009-08-27 | 2011-03-03 | 株式会社 イギス | 鼻炎治療剤 |
| MX353295B (es) | 2011-01-21 | 2018-01-08 | Endo Kyoko | Agente para el tratamiento de la alopecia. |
| CA2986086A1 (en) | 2015-05-29 | 2016-12-08 | Igisu Co., Ltd. | Cyclyc peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2256952T3 (es) * | 1997-09-11 | 2006-07-16 | SHIONOGI & CO., LTD. | Inmunoanalisis para bnp. |
-
2005
- 2005-01-27 JP JP2006550367A patent/JP2007525213A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006500949A5 (https=) | ||
| JP2010115195A5 (https=) | ||
| JP2002534062A5 (https=) | ||
| JP2013536442A5 (https=) | ||
| MX2009001459A (es) | Polipeptidos diureticos y natriureticos. | |
| RU2663724C2 (ru) | Способы определения восприимчивости пациента к внутрибольничной инфекции и составления прогноза развития септического синдрома | |
| CA3036411A1 (en) | Assay for distinguishing between sepsis and systemic inflammatory response syndrome | |
| Su et al. | Expression of oncogene products HER2/Neu and Ras and fibrosis-related growth factors bFGF, TGF-β, and PDGF in bile from biliary malignancies and inflammatory disorders | |
| JP2002517244A5 (https=) | ||
| CN110402393A (zh) | 疾病诊断的组合物 | |
| JP2008502332A5 (https=) | ||
| CN112424609A (zh) | 卒中的血液生物标志物 | |
| JP2007525213A5 (https=) | ||
| CN111212911B (zh) | 与tb7.7特异性结合的dna适体及其用途 | |
| JP2005511023A5 (https=) | ||
| CN105734070A (zh) | Corin基因变异体及其用途 | |
| CN115184605A (zh) | 基于tp0136建立的梅毒病期检测免疫共沉淀试剂盒 | |
| JP2008507261A5 (https=) | ||
| JP2007526763A5 (https=) | ||
| AU2005320352A2 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer | |
| JP2023145633A5 (https=) | ||
| CN111212910B (zh) | 与cfp10特异性结合的dna适体及其用途 | |
| JP2009523004A5 (https=) | ||
| CN110357948B (zh) | MdrP突变体的基因、氨基酸、蛋白功能及药物积累活性检测 | |
| CN116217701A (zh) | 一种pla2r重组蛋白及其应用 |